drugset / Trial / NCT03679611

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

NCT03679611

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs (NMBD). This study will evaluate whether reversal of NMBD with sugammadex is associated with faster recovery than neostigmine resulting in faster discharge from the operating room (OR) in obese patients with OSA undergoing bariatric surgery. Half of the patients in the study will receive sugammadex and the other half of the patients will receive neostigmine.

Timeline

Start
2019-01-14
Primary completion
2021-10-26
Completion
2021-10-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 2.5 mg
Subject Sugammadex Other / unclassified 2 mg/kg